Status:
COMPLETED
Idiopathic Pulmonary Fibrosis and Serum Bank
Lead Sponsor:
Rennes University Hospital
Conditions:
Idiopathic Pulmonary Fibrosis
Lung Diseases, Interstitial
Eligibility:
All Genders
18+ years
Brief Summary
Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause,...
Detailed Description
This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.
Eligibility Criteria
Inclusion
- Patients seen on an outpatient basis and in stable or acute condition
- Patient over 18 years of age.
- The inclusion criteria will be those edited by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to diagnosis IPF
Exclusion
- Patients who are unable or unwilling to sign the consent.
Key Trial Info
Start Date :
October 22 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2022
Estimated Enrollment :
903 Patients enrolled
Trial Details
Trial ID
NCT04016168
Start Date
October 22 2014
End Date
December 28 2022
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rennes University Hospital - Service de Pneumologie
Rennes, France, 35033